Addition of Levetiracetam May Improve Survival for Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy, a recent study published online in the journal Cancer has shown.

For the study, researchers identified 103 patients with primary glioblastoma who received comcomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide. Of those, 56% received levetiracetam during temozolomide chemotherapy for at least 3 months.

Results showed that median progression-free survival was 9.4 months (95% CI: 7.5-11.3) among those who took levetiracetam compared with 6.7 months (95% CI: 5.8-7.6) among those who did not receive the drug (P = 0.010). Median overall survival was 25.7 (95% CI: 21.7-29.7) and 16.7 months (95% CI: 12.1-21.3), respectively (P = 0.027).

The findings suggest that levetiracetam may improve survival in this patient population, but the authors note that a randomized study is warranted.

Previous studies have suggested the chemosensitizing effect of levetiracetam, an antiepileptic drug, but data surrounding survival benefit is lacking.

Transformation of White Fat to Brown Fat Drives Cachexia
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
A chemosensitizing effect of levetiracetam (LEV) has been suggested because LEV inhibits O-6 methylguanine-DNA methyltransferase (MGMT).
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs